Anthony F. Cordova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anthony F. Cordova has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Lingyin Li
Department of Biochemistry, Stanford University; Stanford, CA 94305, USA
6 shared publications Volker Böhnert
ChEM-H Institute, Stanford University, Stanford, CA 94301
3 shared publications- Christopher Ritchie
Stanford University
2 shared publications Gemini Skariah
ChEM-H Institute, Stanford University, Stanford, CA 94301
2 shared publicationsRachel E. Mardjuki
ChEM-H Institute, Stanford University, Stanford, CA 94301
2 shared publications- Xujun Cao
Stanford University
2 shared publications
Latest Publications
- Open Access
- 19 May 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (21)
ENPP1’s regulation of extracellular cGAMP is a ubiquitous mechanism of attenuating STING signaling
Significance: The immune system strikes a careful balance between launching a robust response to threats and avoiding overactivation. The molecule cGAMP is an immunotransmitter that activates innate immunity and signals extracellularly, where it is subject to degradation by the enzyme ENPP1. Here, we engineer ENPP1 to lose activity toward cGAMP but not other substrates, thus creating a biochemically precise tool to understand how ENPP1 regulates extracellular cGAMP and thus innate immunity. We uncover that ENPP1's degradation of extracellular cGAMP has a long evolutionary history, and that this mechanism is critical for controlling diverse immune threats, including viral infection and inflammation.
- 19 May 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (21)
Open AccessENPP1’s regulation of extracellular cGAMP is a ubiquitous mechanism of attenuating STING signaling
Significance: The immune system strikes a careful balance between launching a robust response to threats and avoiding overactivation. The molecule cGAMP is an immunotransmitter that activates innate immunity and signals extracellularly, where it is subject to degradation by the enzyme ENPP1. Here, we engineer ENPP1 to lose activity toward cGAMP but not other substrates, thus creating a biochemically precise tool to understand how ENPP1 regulates extracellular cGAMP and thus innate immunity. We uncover that ENPP1's degradation of extracellular cGAMP has a long evolutionary history, and that this mechanism is critical for controlling diverse immune threats, including viral infection and inflammation.
- 6 December 2021
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 122 (3) , 3414-3458
Therapeutic Interventions Targeting Innate Immune Receptors: A Balancing Act
The innate immune system is an organism’s first line of defense against an onslaught of internal and external threats. The downstream adaptive immune system has been a popular target for therapeutic intervention, while there is a relative paucity of therapeutics targeting the innate immune system. However, the innate immune system plays a critical role in many human diseases, such as microbial infection, cancer, and autoimmunity, highlighting the need for ongoing therapeutic research. In this review, we discuss the major innate immune pathways and detail the molecular strategies underpinning successful therapeutics targeting each pathway as well as previous and ongoing efforts. We will also discuss any recent discoveries that could inform the development of novel therapeutic strategies. As our understanding of the innate immune system continues to develop, we envision that therapies harnessing the power of the innate immune system will become the mainstay of treatment for a wide variety of human diseases.
- 6 December 2021
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 122 (3) , 3414-3458
Therapeutic Interventions Targeting Innate Immune Receptors: A Balancing Act
The innate immune system is an organism’s first line of defense against an onslaught of internal and external threats. The downstream adaptive immune system has been a popular target for therapeutic intervention, while there is a relative paucity of therapeutics targeting the innate immune system. However, the innate immune system plays a critical role in many human diseases, such as microbial infection, cancer, and autoimmunity, highlighting the need for ongoing therapeutic research. In this review, we discuss the major innate immune pathways and detail the molecular strategies underpinning successful therapeutics targeting each pathway as well as previous and ongoing efforts. We will also discuss any recent discoveries that could inform the development of novel therapeutic strategies. As our understanding of the innate immune system continues to develop, we envision that therapies harnessing the power of the innate immune system will become the mainstay of treatment for a wide variety of human diseases.
- Open Access
Probing pathophysiology of extracellular cGAMP with substrate-selective ENPP1
The biology of the immune second messenger cGAMP depends on its cellular localization. cGAMP, which is synthesized in response to cytosolic double-stranded DNA, also exists in the extracellular space as a paracrine immunotransmitter that enhances the anticancer immune response. However, the role of extracellular cGAMP is unexplored outside of cancer due to a lack of tools to systemically manipulate it. The extracellular enzyme ENPP1, the only known hydrolase of cGAMP, is a promising target. However, because ENPP1 also degrades extracellular ATP, using genetic knockouts of ENPP1 to study extracellular cGAMP leads to confounding effects. Here we report the H362A point mutation in ENPP1, the dominant cGAMP hydrolase, which selectively abolishes ENPP1’s ability to degrade cGAMP, while retaining activity toward other substrates. H362 is not necessary for binding cGAMP or the catalytically-essential zinc atoms but instead supports the in-line reaction geometry. H362 is evolutionarily conserved down to bacteria, suggesting an ancient origin for extracellular cGAMP biology. Enpp1 H362A mice do not display the systemic calcification seen in Enpp1 -/- mice, highlighting the substrate-specific phenotype of ENPP1. Remarkably, Enpp1 H362A mice were resistant to HSV-1 infection, demonstrating the antiviral role of endogenous extracellular cGAMP. The ENPP1 H362A mutation is the first genetic tool to enable exploration of extracellular cGAMP biology in a wide range of tissues and diseases.
Open AccessProbing pathophysiology of extracellular cGAMP with substrate-selective ENPP1
The biology of the immune second messenger cGAMP depends on its cellular localization. cGAMP, which is synthesized in response to cytosolic double-stranded DNA, also exists in the extracellular space as a paracrine immunotransmitter that enhances the anticancer immune response. However, the role of extracellular cGAMP is unexplored outside of cancer due to a lack of tools to systemically manipulate it. The extracellular enzyme ENPP1, the only known hydrolase of cGAMP, is a promising target. However, because ENPP1 also degrades extracellular ATP, using genetic knockouts of ENPP1 to study extracellular cGAMP leads to confounding effects. Here we report the H362A point mutation in ENPP1, the dominant cGAMP hydrolase, which selectively abolishes ENPP1’s ability to degrade cGAMP, while retaining activity toward other substrates. H362 is not necessary for binding cGAMP or the catalytically-essential zinc atoms but instead supports the in-line reaction geometry. H362 is evolutionarily conserved down to bacteria, suggesting an ancient origin for extracellular cGAMP biology. Enpp1 H362A mice do not display the systemic calcification seen in Enpp1 -/- mice, highlighting the substrate-specific phenotype of ENPP1. Remarkably, Enpp1 H362A mice were resistant to HSV-1 infection, demonstrating the antiviral role of endogenous extracellular cGAMP. The ENPP1 H362A mutation is the first genetic tool to enable exploration of extracellular cGAMP biology in a wide range of tissues and diseases.
- Open Access
Human SLC46A2 is the dominant cGAMP importer in extracellular cGAMP-sensing macrophages and monocytes
Administration of exogenous CDNs to activate the cGAMP-STING pathway is a promising therapeutic strategy to unleash the full potential of cancer immunotherapy. This strategy mirrors the role of endogenous extracellular cGAMP, which we recently described as an immunotransmitter exported by cancer cells and imported into local responder cells of unknown identities to promote anti-tumoral immunity, with irradiation enhancing this effect. Here, in low-dose irradiated murine tumors, we identified CD4+ T cells, M1 macrophages, and NKG2DLow NK cells as cGAMP responder cells that have decreased STING activation upon depletion of extracellular cGAMP. At higher doses of radiation, extracellular cGAMP promoted the death of T cells and macrophages. Furthermore, we identified the orphan protein SLC46A2 as the dominant importer of cGAMP and select bacterial CDNs in human macrophages and monocytes. Together, we provide the first cellular and molecular mechanisms of cGAMP as an immunotransmitter, paving the way for effective STING pathway therapeutics.
Open AccessHuman SLC46A2 is the dominant cGAMP importer in extracellular cGAMP-sensing macrophages and monocytes
Administration of exogenous CDNs to activate the cGAMP-STING pathway is a promising therapeutic strategy to unleash the full potential of cancer immunotherapy. This strategy mirrors the role of endogenous extracellular cGAMP, which we recently described as an immunotransmitter exported by cancer cells and imported into local responder cells of unknown identities to promote anti-tumoral immunity, with irradiation enhancing this effect. Here, in low-dose irradiated murine tumors, we identified CD4+ T cells, M1 macrophages, and NKG2DLow NK cells as cGAMP responder cells that have decreased STING activation upon depletion of extracellular cGAMP. At higher doses of radiation, extracellular cGAMP promoted the death of T cells and macrophages. Furthermore, we identified the orphan protein SLC46A2 as the dominant importer of cGAMP and select bacterial CDNs in human macrophages and monocytes. Together, we provide the first cellular and molecular mechanisms of cGAMP as an immunotransmitter, paving the way for effective STING pathway therapeutics.
- Open Access
In response to Luteijn et al .: Concerns regarding cGAMP uptake assay and evidence that SLC19A1 is not the major cGAMP importer in human PBMCs
We previously reported that SLC19A1 is an importer of the immunotransmitter 2’3’-cyclic-GMP-AMP (cGAMP) 1 by performing a genome wide screen in U937 cells. Soon after, Lutejin et al . reported similar findings by conducting a screen in THP-1 cells 2 . While the conclusions of these two studies largely overlap, we arrived at significantly different conclusions regarding how broadly SLC19A1 is used by different cell types. Our study suggests that in addition to SLC19A1, many cultured and primary cell types use alternative, unidentified transporters to import cGAMP and other cyclic dinucleotides (CDNs). This conclusion was based on our findings that inhibition of SLC19A1 did not significantly reduce extracellular cGAMP signaling in multiple cell types, including primary CD14 + peripheral blood mononuclear cells (PBMCs) from most donors. In contrast, Luteijn et al . concluded that SLC19A1 is the major CDN importer in humans, largely based on their use of a radiolabeled [ 32 P] cGAMP uptake assay. Using this assay, they showed that inhibition of SLC19A1 abolishes [ 32 P] uptake in total PBMCs. However, they did not test whether inhibition of SLC19A1 affects extracellular cGAMP signaling in these cells. Here, we highlight an important issue with the [ 32 P] cGAMP uptake assay used by Luteijn et al . and demonstrate that measuring extracellular cGAMP signaling through the STING pathway is currently the best method for evaluating cGAMP import. We also show that inhibition of SLC19A1 has no effect on extracellular cGAMP signaling in total PBMCs, confirming that this cell type relies on other transport mechanisms for cGAMP import.
Open AccessIn response to Luteijn et al .: Concerns regarding cGAMP uptake assay and evidence that SLC19A1 is not the major cGAMP importer in human PBMCs
We previously reported that SLC19A1 is an importer of the immunotransmitter 2’3’-cyclic-GMP-AMP (cGAMP) 1 by performing a genome wide screen in U937 cells. Soon after, Lutejin et al . reported similar findings by conducting a screen in THP-1 cells 2 . While the conclusions of these two studies largely overlap, we arrived at significantly different conclusions regarding how broadly SLC19A1 is used by different cell types. Our study suggests that in addition to SLC19A1, many cultured and primary cell types use alternative, unidentified transporters to import cGAMP and other cyclic dinucleotides (CDNs). This conclusion was based on our findings that inhibition of SLC19A1 did not significantly reduce extracellular cGAMP signaling in multiple cell types, including primary CD14 + peripheral blood mononuclear cells (PBMCs) from most donors. In contrast, Luteijn et al . concluded that SLC19A1 is the major CDN importer in humans, largely based on their use of a radiolabeled [ 32 P] cGAMP uptake assay. Using this assay, they showed that inhibition of SLC19A1 abolishes [ 32 P] uptake in total PBMCs. However, they did not test whether inhibition of SLC19A1 affects extracellular cGAMP signaling in these cells. Here, we highlight an important issue with the [ 32 P] cGAMP uptake assay used by Luteijn et al . and demonstrate that measuring extracellular cGAMP signaling through the STING pathway is currently the best method for evaluating cGAMP import. We also show that inhibition of SLC19A1 has no effect on extracellular cGAMP signaling in total PBMCs, confirming that this cell type relies on other transport mechanisms for cGAMP import.
- 1 July 2019
- Published by Elsevier in Molecular Cell
- Vol. 75 (2) , 372-381.e5
SLC19A1 Is an Importer of the Immunotransmitter cGAMP
- 1 July 2019
- Published by Elsevier in Molecular Cell
- Vol. 75 (2) , 372-381.e5
SLC19A1 Is an Importer of the Immunotransmitter cGAMP